title: Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain.
abstract: Studies of the pathogenesis and molecular biology of JC virus infection over the last two decades have significantly changed our understanding of progressive multifocal leukoencephalopathy, which can be described as a subacute viral infection of neuroglial cells that probably follows reactivation of latent infection rather than being the consequence of prolonged JC virus replication in the brain. There is now sufficient evidence to suggest that JC virus latency occurs in kidney and B cells. However, JC virus isolates from brain or kidney differ in the regulatory regions of their viral genomes which are controlled by host cell factors for viral gene expression and replication. DNA sequences of noncoding regions of the viral genome display a certain heterogeneity among isolates from brain and kidney. These data suggest that an archetypal strain of JC virus exists whose sequence is altered during replication in different cell types. The JC virus regulatory region likely plays a significant role in establishing viral latency and must be acted upon for reactivation of the virus. A developing hypothesis is that reactivation takes place from latently infected B lymphocytes that are activated as a result of immune suppression. JC virus enters the brain in the activated B cell. Evidence for this mechanism is the detection of JC virus DNA in peripheral blood lymphocytes and infected B cells in the brains of patients with progressive multifocal leukoencephalopathy. Once virus enters the brain, astrocytes as well as oligodendrocytes support JC virus multiplication. Therefore, JC virus infection of neuroglial cells may impair other neuroglial functions besides the production and maintenance of myelin. Consequently our increased understanding of the pathogenesis of progressive multifocal leukoencephalopathy suggests new ways to intervene in JC virus infection with immunomodulation therapies. Perhaps along with trials of nucleoside analogs or interferon administration, this fatal disease, for which no consensus of antiviral therapy exists, may yield to innovative treatment protocols.
authors.affiliation: Section on Molecular Virology and Genetics, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland 20892.
authors.forename: E O
authors.initials: EO
authors.lastname: Major
authors.forename: K
authors.initials: K
authors.lastname: Amemiya
authors.forename: C S
authors.initials: CS
authors.lastname: Tornatore
authors.forename: S A
authors.initials: SA
authors.lastname: Houff
authors.forename: J R
authors.initials: JR
authors.lastname: Berger
mesh_terms: D000818:Animals; D001483:Base Sequence; D001921:Brain / Q000382:microbiology; D001927:Brain Diseases / Q000188:drug therapy / Q000209:etiology*; D001932:Brain Neoplasms / Q000209:etiology; D002460:Cell Line; D006224:Cricetinae; D003711:Demyelinating Diseases / Q000188:drug therapy / Q000209:etiology*; D005814:Genes, Viral; D006801:Humans; D007577:JC Virus / Q000235:genetics* / Q000302:isolation & purification / Q000472:pathogenicity; D051379:Mice; D008969:Molecular Sequence Data; D014412:Tumor Virus Infections